PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Coronavirus tracker: Amgen, Genfit say they’re not expecting ‘significant’ trial delays, though others might

Amgen said it doesn’t expect any “significant delays” to the clinical development of its highly anticipated KRAS lung cancer drug—nor does Genfit with its NASH candidate. However, Akero Therapeutics said it’s about halfway through collecting biopsies for its own NASH drug, and it isn’t clear at the moment how much COVID-19 will interfere.

Meanwhile, the FDA and the FTC are sifting through social media posts and online ads for fraudulent coronavirus therapies—and have delivered stern warnings to websites offering “infection prevention nasal spray” or herbal remedies and cures.

As of Tuesday, the number of global confirmed cases has surpassed 838,000, according to Johns Hopkins University’s real-time dashboard, and more than 41,250 people have died.

Amgen said it doesn’t expect to see any “significant delays” to the development of its highly anticipated KRAS cancer drug, AMG 510, due to the spreading pandemic. The Big Pharma said its potentially pivotal phase 2 study is already fully enrolled with lung cancer patients. 

Genfit told its investors the same regarding the upcoming unblinding of its phase 3 elafibranor study in nonalcoholic steatohepatitis, or NASH. The company doesn’t “currently anticipate” that COVID-19 will delay its results; however, Genfit has already pushed back the release since its February database lock to gather feedback from the FDA. 

Akero Therapeutics, however, may not be so lucky. It planned to report top-line phase 2a NASH data from its drug AKR-001 in the second quarter—but it is currently about halfway through collecting biopsies. “The extent to which the COVID-19 pandemic will interfere with collection of the remaining biopsies and data from other scheduled clinical visits, including the safety follow-up visit at week 20, is unclear,” the company said.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026